Vantage Press & Media
SIGNATURE HEALTHCARE RADIATION THERAPY CENTER AND VANTAGE ONCOLOGY OFFER NEW TREATMENT ALTERNATIVE FOR
EARLY STAGE BREAST CANCER
Axxent® Electronic Brachytherapy System from Xoft Inc. Delivers Localized Therapy Directly To Cancer Sites in Minimally Shielded
Clinical Setting
BROCKTON, MA – Women of Eastern Massachusetts with early stage breast cancer now have a new treatment option available to help reduce the chances of recurrence. Signature Healthcare Radiation Therapy Center and Vantage Oncology today announced that they will offer Axxent® Electronic Brachytherapy, which uses a miniaturized X-ray source that can deliver localized and targeted radiation treatments under the supervision of a radiation oncologist.
“We are proud to offer our patients an exciting new way to deliver radiation therapy for the treatment of breast cancer,” said Steven Lane, M.D., a radiation oncologist at Signature Healthcare Radiation Therapy Center. “Electronic Brachytherapy uses an electronic X-ray source, as opposed to radioactive isotopes, enabling it to be delivered in minimally-shielded environments. The result is on-demand X-ray treatments that we expect will improve access to critical radiation therapy.”
Data from several randomized controlled clinical studies has demonstrated that radiation therapy is an essential component of treatment for breast cancer following lumpectomy. Radiation therapy is administered after breast-sparing surgery with the intent of eliminating stray cancer cells that may remain in the breast. For appropriate patients with early stage breast cancer; lumpectomy followed by radiation is proven to reduce the rate of local recurrences and gives equivalent results when compared to a mastectomy.
Approved by the U.S. Food & Drug Administration (FDA) for the treatment of early stage breast cancer, the Axxent Electronic Brachytherapy System is designed to deliver radiation therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. In addition, the system reduces the time required for radiation therapy for early stage breast cancer from seven weeks for external radiation therapy to five days. As a result, tens of thousands of patients will have greater access to therapy that can be delivered more easily and conveniently. This may redirect patient choice to breast conservation therapy with a lumpectomy followed by radiation therapy over the alternative of a mastectomy.
“We continue to offer state-of-the-art radiation technology such as the TomoTherapy® Hi-Art and the Axxent Electronic Brachytherapy Systems to our community. We have incorporated Axxent into our cancer center in order to provide a revolutionary radiation treatment alternative to our breast cancer patients in a convenient and comfortable environment,” said Dr. Lane.
ABOUT SIGNATURE HEALTHCARE BROCKTON HOSPITAL
Signature Healthcare Brockton Hospital is a 268-bed private, not-for-profit teaching hospital and serves as the only full-service hospital in the region. The hospital offers centers of excellence in Cardiology, Emergency Medicine, Maternity Care, and Radiation Therapy. Recently, Signature Healthcare Brockton Hospital became the only hospital in the area to offer emergency angioplasty services 24 hours a day, 7 days a week for patients experiencing a heart attack and is now among a select group of community hospitals offering elective angioplasty for patients meeting certain criteria as part of the MassCOMM study. The hospital is a state-designated regional site for radiation therapy and cardiac catheterization. For more information about Signature Healthcare Brockton Hospital, visit www.Signature-Healthcare.org.
ABOUT VANTAGE ONCOLOGY, INC.
Founded in October 2002, Vantage Oncology, Inc. (“Vantage”) acquires, joint ventures, develops and operates radiation oncology centers of excellence. The Company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage is led by a seasoned management team, including co-founder and Chief Executive Officer Michael Fiore, co-founder and Chief Medical Officer Leslie Botnick, M.D., Chief Financial Officer Marshal Salomon, Chief Development Officer Mark Ahern and Chief Technology Officer Christopher Rose, M.D. For more information about Vantage, visit www.vantageoncology.com.
ABOUT XOFT, INC.
Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized x-ray tube technology. The Axxent® Electronic Brachytherapy System, Xoft's first treatment system, is designed for use in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes. For more information about Xoft, visit www.XoftInc.com.
CONTACT:
Trace Longo
Longo Communications
(949) 364-2821
Vantage Oncology
Marketing Dept.
(310) 335-4000
|
